| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
For the Quarter Ended March 31, 2026 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
226,154 |
|
$ |
85,586 |
|
$ |
311,740 |
Intersegment |
|
|
|
|
|
|
|
(325) |
Consolidated net sales |
|
|
|
|
|
|
$ |
311,415 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
53,794 |
|
|
38,649 |
|
|
|
Selling, general and administrative |
|
57,909 |
|
|
27,616 |
|
|
|
Research and development |
|
14,452 |
|
|
9,002 |
|
|
|
Segment operating income |
$ |
99,999 |
|
$ |
10,319 |
|
$ |
110,318 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(15,382) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(897) |
Certain litigation charges |
|
|
|
|
|
|
|
(822) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(10,968) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(2,952) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(3,802) |
Consolidated operating income |
|
|
|
|
|
|
$ |
75,495 |
|
|
|
|
|
|
|
|
|
For the Quarter Ended March 31, 2025 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
227,687 |
|
$ |
89,231 |
|
$ |
316,918 |
Other revenue(1) |
|
|
|
|
|
|
|
— |
Intersegment |
|
|
|
|
|
|
|
(737) |
Consolidated net sales |
|
|
|
|
|
|
$ |
316,181 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
53,193 |
|
|
37,189 |
|
|
|
Selling, general and administrative |
|
55,804 |
|
|
33,419 |
|
|
|
Research and development |
|
14,780 |
|
|
10,200 |
|
|
|
Segment operating income |
$ |
103,910 |
|
$ |
8,423 |
|
$ |
112,333 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(18,836) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(5,159) |
Certain litigation charges |
|
|
|
|
|
|
|
(38,927) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(11,629) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(716) |
Recovery of assets held-for-sale |
|
|
|
|
|
|
|
3,655 |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(2,013) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
— |
Consolidated operating income |
|
|
|
|
|
|
$ |
38,708 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.
|
|
|
|
|
|
|
|
|
For the Nine Months Ended March 31, 2026 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
643,426 |
|
$ |
246,224 |
|
$ |
889,650 |
Other revenue |
|
|
|
|
|
|
|
5,439 |
Intersegment |
|
|
|
|
|
|
|
(1,242) |
Consolidated net sales |
|
|
|
|
|
|
$ |
893,847 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
161,342 |
|
|
108,857 |
|
|
|
Selling, general and administrative |
|
176,668 |
|
|
83,064 |
|
|
|
Research and development |
|
43,089 |
|
|
26,674 |
|
|
|
Segment operating income |
$ |
262,327 |
|
$ |
27,629 |
|
$ |
289,956 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(46,111) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(6,341) |
Certain litigation charges |
|
|
|
|
|
|
|
(5,370) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(37,262) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(14,201) |
Recovery of assets held-for-sale |
|
|
|
|
|
|
|
6,789 |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(7,273) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
(2,573) |
Consolidated operating income |
|
|
|
|
|
|
$ |
177,614 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since June 30, 2025.
|
|
|
|
|
|
|
|
|
For the Nine Months Ended March 31, 2025 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
643,774 |
|
$ |
256,558 |
|
$ |
900,332 |
Other revenue(1) |
|
|
|
|
|
|
|
4,152 |
Intersegment |
|
|
|
|
|
|
|
(1,813) |
Consolidated net sales |
|
|
|
|
|
|
$ |
902,671 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
157,618 |
|
|
108,417 |
|
|
|
Selling, general and administrative |
|
170,420 |
|
|
102,002 |
|
|
|
Research and development |
|
44,172 |
|
|
30,199 |
|
|
|
Segment operating income |
$ |
271,564 |
|
$ |
15,940 |
|
$ |
287,504 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
(57,136) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(9,051) |
Certain litigation charges |
|
|
|
|
|
|
|
(40,606) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(37,504) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(15,027) |
Recovery of assets held-for-sale |
|
|
|
|
|
|
|
3,655 |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(5,241) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
(479) |
Consolidated operating income |
|
|
|
|
|
|
$ |
126,115 |
(1) Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.
|